August 27, 2025

Emerging PD-1 Inhibitor Plus Chemotherapy Shows Efficacy in Second-Line Classical Hodgkin Lymphoma

The addition of the PD-1 inhibitor sintilimab to ICE (ifosfamide, carboplatin, and etoposide) chemotherapy appeared to significantly improve the complete remission rate and showed a trend toward impro...

The ASCO Post

August 25, 2025

Discontinuation and Resumption of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors

As reported in the Journal of Clinical Oncology by Mascarenhas et al, follow-up of a cohort of pediatric patients with TRK fusion sarcomas and related mesenchymal tumors treated with larotrectinib sho...

The ASCO Post

August 25, 2025

Botensilimab Plus Balstilimab in Relapsed or Refractory Metastatic Sarcomas

In a phase Ib study reported in the Journal of Clinical Oncology, Wilky et al found that the combination of botensilimab (Fc-enhanced anti–CTLA-4 antibody) and balstilimab (anti–PD-1 antibody) yielded...

The ASCO Post

August 25, 2025

High-Risk Rhabdomyosarcoma: Long-Term Outcomes With Maintenance Chemotherapy

Long-term follow-up of the European Paediatric Soft Tissue Sarcoma Study Group RMS2005 trial was recently reported.

The ASCO Post

August 25, 2025

Digital Histopathology and Automated Classification of Pediatric Sarcomas

With more than 50 different subtypes, pediatric soft-tissue sarcomas represent a broad category of disease. And given the rarity of these sarcomas, “it is difficult for pathologists to see a sufficien...

The ASCO Post

August 22, 2025

Older Women With High-Risk Breast Cancer: Addition of Adjuvant Chemotherapy to Hormone Therapy

In a French-Belgian phase III trial (ASTER 70s) reported in The Lancet, Brain et al examined the survival benefit of adding adjuvant chemotherapy to hormone therapy in women aged ≥ 70 years with estro...

The ASCO Post

August 22, 2025

Can Baseline PSMA-PET Help to Predict Response to LuPSMA and Enzalutamide in mCRPC?

In a substudy of the Australian phase II ENZA-p trial, baseline PSMA-PET total tumor volume was prognostic for overall survival and predictive for a beneficial effect on overall survival in patients r...

The ASCO Post

August 22, 2025

Breast Cancer Surveillance in Pre– vs Post–COVID-19 Periods

In a study reported as a research letter in JAMA Oncology, Hahn et al found that the proportion of U.S. patients with breast cancer undergoing annual surveillance imaging was lower in the post– vs pre...

The ASCO Post

August 22, 2025

EBRT With Focal Boost in Localized Prostate Cancer: 10-Year Follow-up

As reported in the Journal of Clinical Oncology by Guricová et al, 10-year outcomes of the Dutch-Belgian phase III FLAME trial showed continued benefit of a focal radiotherapy boost to the intraprosta...

The ASCO Post